Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

US FDA probes cardio events, deaths in Sanofi halted Multaq study

This article was originally published in Scrip

Executive Summary

Two weeks after Sanofi halted a Phase IIIb study of its antiarrhythmic drug Multaq (dronedarone) in patients with permanent atrial fibrillation at the behest of the trial's data monitoring committee after a two-fold increase in death, stroke and heart failure-related hospitalizations were identified, the US FDA said it was taking up an examination of the data (scripintelligence, 8 July 2011).

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

SC013801

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel